Identifying breakthroughs and filling gaps in the treatment landscape
Directing research to the areas of greatest need.
Funding trials that benefit children over research for research sake.
Developing streamlined clinical trials that quickly advance promising options.
SKC Presence in the Research Landscape
Over the past decade, Solving Kids’ Cancer has earned a seat at the table among some of the most inspiring researchers and other like-minded organizations that are making significant impact in the pediatric cancer research landscape.
As a member of the NCI’s Pediatric Central Institutional Review Board, SKC has a voice in every clinical trial that is reviewed by the Children’s Oncology Group (COG) which is the world’s largest organization devoted exclusively to childhood cancer research with more than 200 participating hospitals.
SKC participates in consortiums, coalitions, and committees worldwide.
FDA Patient Representative and FDA Oncologic Drugs Advisory Committee (2010 - present)
NANT Advisory Council, member and chair (2010-present)
Coalition Against Childhood Cancer (CAC2), Founding Member and Board Member (2012-present)
Society for Immunotherapy of Cancer, member, (2013-present)
AACR Pediatric Cancer Working Group Steering Committee (2015-present)
National Cancer Institute, Pediatric Central Institutional Review Board (2015-present)
SKC has been invited to present at conferences and meetings around the world.
Children’s Oncology Group, Educational Presenter (2010-2012)
American Association for Hemotology/Oncology Nurses, Educational Presenter (2011)
Children's Neuroblastoma Cancer Foundation, Presenter (2010-2012)
Neuroblastoma Children's Cancer Alliance, Presenter, England (2011-2015)
The International Society for Pediatric Oncology, Presenter (2011)
FDA Advisory Committee, FDA (2011)
Bristol-Meyers Squibb Advocate Council meeting, Presenter (2015)
NCI Genomics Workshop, Advocate, Embryonal tumor panel member (2015)
Advances in Neuroblastoma Research Association, Presenter, Australia (2016)
AACR Pediatric Cancer Predisposition Workshop, Boston (2016)
CAC2 Research Conference, Organizing Committee, Cold Spring Harbor Laboratory, NY (2016)
AACR Annual meeting, Pediatric Cancer Drug Development, Panel Member, New Orleans (2016) International Society of Pediatric Oncology, Poster Session Presenter, Washington, DC (2017)
Solving Kids' Cancer advocates for systemic improvements in the research enterprise and initiates novel clinical trials for children battling the deadliest childhood cancers. Experts agree that cures will come through multimodal combinations and approaches. SKC supports innovative therapies with strong rationale for improved outcomes for children who need it the most.
SKC has funded 34 pediatric cancer research projects, 12 studies are currently enrolling and 4 new trials are set to open in 2018.
25 of these projects represent clinical trials accruing hundreds of children at cancer centers in 5 countries.
SKC has supported 9 preclinical investigative projects, 3 of these, based on findings, led to clinical trials.
SKC has initiated 2 transatlantic clinical trials, with a third in the planning, expanding access to children in UK and Europe.
SKC has collaboratively funded 17 projects with 19 charity partners
SKC has supported ground-breaking clinical trials testing four different oncolytic viruses, dendritic cell and whole tumor vaccines, antibodies in combination with other agents and cellular therapies, targeted small molecules, emerging technologies such as high-intensity focused ultrasound, and convection-enhanced delivery, T cell CARs and CTLs, next-generation precision medicine, and haplo-identical stem cell transplant.
SKC has issued 5 requests for proposals with plans to issue 2 more in 2018 to address unmet needs in metastatic sarcomas and induction therapies for neuroblastoma.